GLPGF News and Press, Galapagos Genomics Ord From 02/27/23

Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) community New analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca ® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be pres...

Galapagos NV (GLPG) Q4 2022 Earnings Conference Call February 24, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D&...

Key 202 2 and post - period events Dr. Paul Stoffels i appointed as Chief Executive Officer and Chairman of the Board of Directors Implemented new strategic direction to accelerate innovation and time-to-patients: Set-up of new innovation model and fit-for-pu...

Summary On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory. We...

All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter’s transformation, responded to treatment (Objective Response Rate of 100%) GLPG5201 showed an acceptable safety profile with no cytokine release syndrome (CRS) higher than gr...

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10 In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58 The safety findings were gene...

Mechelen, Belgium; 10 January 202 3 , 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1 , Galapagos receiv...

Summary GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing. They have a huge cash stockpile. I haven’t covered Galapagos ( GLPG ) in a while. My last coverage of t...

Summary David Einhorn's 13F stock portfolio value increased from $1.29B to $1.41B this quarter. Greenlight increased Kyndryl Holdings, LivaNova PLC, and Southwestern Energy while dropping Chemours, International Seaways, and Warner Bros. Discovery. The largest three positions are at...

Summary David Einhorn's 13F stock portfolio value decreased from $1.57B to $1.29B this quarter. Greenlight increased Atlas Air Worldwide, Kyndryl Holdings, and Victoria’s Secret while decreasing Teck Resources, Change Healthcare, Chemours, and International Seaways. They al...